Strongbridge Biopharma Stock Forecast, Price & News

Strongbridge Biopharma (NASDAQ:SBBP) Frequently Asked Questions

Is Strongbridge Biopharma a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Strongbridge Biopharma in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Strongbridge Biopharma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SBBP, but not buy additional shares or sell existing shares.
View analyst ratings for Strongbridge Biopharma or view top-rated stocks.

How were Strongbridge Biopharma's earnings last quarter?

Strongbridge Biopharma plc (NASDAQ:SBBP) released its quarterly earnings results on Thursday, August, 5th. The biotechnology company reported ($0.21) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.12) by $0.09. The biotechnology company had revenue of $10.04 million for the quarter, compared to analysts' expectations of $8.83 million. Strongbridge Biopharma had a negative trailing twelve-month return on equity of 66.82% and a negative net margin of 115.67%.
View Strongbridge Biopharma's earnings history.

What guidance has Strongbridge Biopharma issued on next quarter's earnings?

Strongbridge Biopharma issued an update on its FY 2021 earnings guidance on Thursday, September, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $36 M-, compared to the consensus revenue estimate of $36.28 million.

What price target have analysts set for SBBP?

3 equities research analysts have issued 12-month target prices for Strongbridge Biopharma's stock. Their forecasts range from $3.25 to $10.00. On average, they expect Strongbridge Biopharma's stock price to reach $6.63 in the next year. This suggests a possible upside of 231.3% from the stock's current price.
View analysts' price targets for Strongbridge Biopharma or view top-rated stocks among Wall Street analysts.

Who are Strongbridge Biopharma's key executives?

Strongbridge Biopharma's management team includes the following people:

• John H. Johnson, Chief Executive Officer & Director
• Richard S. Kollender, President & Chief Financial Officer
• Fredric Cohen, Chief Medical Officer
• Brian Conner, Chief Compliance Officer
• Peter J. Valentinsson, Senior Vice President-Global Technical Operations

Who are some of Strongbridge Biopharma's key competitors?

Some companies that are related to Strongbridge Biopharma include PyroGenesis Canada (PYR), G1 Therapeutics (GTHX), Avadel Pharmaceuticals (AVDL), ANI Pharmaceuticals (ANIP), Pharming Group (PHAR), ORIC Pharmaceuticals (ORIC), Basilea Pharmaceutica (BPMUF), Karyopharm Therapeutics (KPTI), Ocular Therapeutix (OCUL), BeyondSpring (BYSI), Gracell Biotechnologies (GRCL), Nkarta (NKTX), Calliditas Therapeutics AB (publ) (CALT), Summit Therapeutics (SMMT) and Deciphera Pharmaceuticals (DCPH).
View all of SBBP's competitors.

What other stocks do shareholders of Strongbridge Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Strongbridge Biopharma investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Energy Transfer (ET), Selecta Biosciences (SELB), Rigel Pharmaceuticals (RIGL), Agile Therapeutics (AGRX), Dicerna Pharmaceuticals (DRNA), Dynavax Technologies (DVAX) and Matinas BioPharma (MTNB).

What is Strongbridge Biopharma's stock symbol?

Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."

Who are Strongbridge Biopharma's major shareholders?

Strongbridge Biopharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Caxton Corp (11.83%), Stonepine Capital Management LLC (6.62%), Rubric Capital Management LP (4.53%), Man Group plc (2.90%), Morgan Stanley (2.62%) and Renaissance Technologies LLC (2.02%). Company insiders that own Strongbridge Biopharma stock include Associates LLC Cdk and David N Gill.
View institutional ownership trends for Strongbridge Biopharma.

Which institutional investors are selling Strongbridge Biopharma stock?

SBBP stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Morgan Stanley, Two Sigma Advisers LP, Caxton Corp, Renaissance Technologies LLC, Millennium Management LLC, Weiss Asset Management LP, and OMERS ADMINISTRATION Corp.
View insider buying and selling activity for Strongbridge Biopharma or view top insider-selling stocks.

Which institutional investors are buying Strongbridge Biopharma stock?

SBBP stock was bought by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Man Group plc, Rubric Capital Management LP, Jane Street Group LLC, and Dimensional Fund Advisors LP. Company insiders that have bought Strongbridge Biopharma stock in the last two years include Associates LLC Cdk, and David N Gill.
View insider buying and selling activity for Strongbridge Biopharma or or view top insider-buying stocks.

What is Strongbridge Biopharma's stock price today?

One share of SBBP stock can currently be purchased for approximately $2.00.

How much money does Strongbridge Biopharma make?

Strongbridge Biopharma has a market capitalization of $135.66 million and generates $30.73 million in revenue each year. The biotechnology company earns $-45.08 million in net income (profit) each year or ($0.78) on an earnings per share basis.

How many employees does Strongbridge Biopharma have?

Strongbridge Biopharma employs 72 workers across the globe.

What is Strongbridge Biopharma's official website?

The official website for Strongbridge Biopharma is www.strongbridgebio.com.

Where are Strongbridge Biopharma's headquarters?

Strongbridge Biopharma is headquartered at 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053.

How can I contact Strongbridge Biopharma?

Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at (610) 254-9200 or via email at [email protected].